Liminatus Pharma Inc. (NASDAQ: LIMN) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunology therapies targeting autoimmune and inflammatory disorders. The company leverages its proprietary IMMX™ platform to design small-molecule modulators that address key pathways in innate and adaptive immune responses. Liminatus’s lead candidates are engineered to offer targeted efficacy with improved safety profiles compared with existing treatment options.
Founded in 2018 as a spin-out from Massachusetts Institute of Technology research, Liminatus has assembled a multidisciplinary R&D team with deep expertise in medicinal chemistry, immunology and translational science. Its pipeline includes three programs in various stages of development: an orally administered immunomodulator for rheumatoid arthritis and inflammatory bowel disease, a second-generation compound for rare complement-mediated conditions, and a preclinical asset aimed at neurological autoimmune disorders.
The company is headquartered in Boston, Massachusetts, and maintains clinical and regulatory operations in the United States and Europe. Liminatus collaborates with leading contract research organizations and academic centers to advance its clinical studies, with ongoing Phase 1 and Phase 2 trials enrolling patients across North America and the European Union. These partnerships are designed to accelerate development timelines and expand the global reach of its therapies.
Led by President and CEO Dr. Emily Parker, formerly of Biogen’s neurology research division, and CSO Dr. Mark Reynolds, a veteran immunologist with experience at multiple biotech startups, Liminatus has secured backing from prominent venture capital firms specializing in life sciences. The company’s strategic focus on immune modulation and its robust intellectual property portfolio position it to address significant unmet needs in autoimmune and inflammatory diseases.
AI Generated. May Contain Errors.
